Loading clinical trials...
Loading clinical trials...
Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate With Inadequate Response To TNF Inhibitors
Conditions
Interventions
CP-690,550
CP-690,550
+4 more
Locations
92
United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Farmington, Connecticut, United States
Pfizer Investigational Site
Trumbull, Connecticut, United States
Start Date
October 1, 2009
Primary Completion Date
March 1, 2011
Completion Date
March 1, 2011
Last Updated
December 19, 2018
NCT07017686
NCT05038553
NCT05790356
NCT03429426
NCT06028438
NCT06800157
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions